Mary Bourke is a Partner in Womble Carlyle’s Intellectual Property Practice Group in the firm’s Wilmington, Delaware office. She represents clients in patent litigation related to biotechnology and pharmaceutical matters. Mary has over 25 years of patent litigation experience at both the district court and appellate levels. She has been involved in multiple ANDA litigations and is
knowledgeable about the complexities of litigation under the Hatch-Watchman Act.
She was the co-first chair for Pfizer’s successful defense of Lipitor® against several ANDA filers. Additionally, Mary currently represents Astra Zeneca in multiple
Areas of Practice
litigations involving AstraZeneca’s successful drug CRESTOR®.
Mary also successfully led the litigation team for Lifescan Inc. in an infringement
action filed against it and four other competitors by Roche relating to blood glucose
Mary has experience in all phases of litigation including pretrial, trial and appellate
stages, both domestically and internationally. She also participates in due diligence
activities for major pharmaceutical companies.
In 2010, Mary was recognized as one of the world’s leading life sciences patent
litigators by IAM (Intellectual Asset Management) magazine.
Palmetto Pharmaceuticals LLC v. AstraZeneca Pharmaceuticals LP (D.
AstraZeneca UK Limited et al v. Watson Pharmaceuticals Inc. et al (D.
Salix Pharmaceuticals, Inc. and Dr. Falk Pharma GmbH v. Lupin
Limited and Lupin Pharmaceuticals, Inc. (D. Del.) (APRISO®)
Roche Diagnostics Operations, Inc., et al v. Abbott Diabetes Care, et al.
(LifeScan Inc.) (D.Del.) (One Touch Ultra®)
Novartis Vaccines & Diagnostics, Inc. v. MedImmune, LLC, et al (D.
In re Armodafanil Patent Litigation (Cephalon Inc., et al) (D. Del.)
In re: Rosuvastatin Calcium Patent Litigation, (AstraZeneca Pharmaceuticals LP et al) (Fed. Cir.)
Purdue Pharma Products LP et al (Ortho-McNeil) v. Par Pharmaceuticals
The Brigham and Women’s Hospital, Inc., NPS Pharmaceuticals, Inc. and
Amgen Inc. v. Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd. and Barr Laboratories, Inc. (D. Del.) (SENSIPAR®)
Pfizer Inc. v. Ranbaxy Labs, Ltd. (Fed. Cir.) (LIPITOR®)
Bayer AG v. Biovail Corporation (Fed. Cir.) (PROCARDIA®)
Bayer AG and Bayer Corporation v. Housey Pharmaceuticals, Inc. (Cell
Talecris and Bayer v. Baxter International, et al (D. Del.)
Professional Activities Admitted to bar: 1985, Delaware. Admitted to practice before the U.S. District Court for District of Delaware, 1987; U.S. Court of Appeals for the Third Circuit, 1987; and the U.S. Court of Appeals for the Federal Circuit, 1987. Education B.S.E, 1981, Princeton University, with Honors; J.D., 1984, University of Pittsburgh School of Law.
ก F 3 (Applied Pharmacotherapeutics I I) 3620 F 132 Email address: [email protected] Integration of epidemiology, pathophysiology, clinical signs and symptoms, and principles of diagnosis and treatment of advanced cardiovascular disorders, disorders of skeletal, bone and joint systems, complicated infectious diseases including dengue fever, acid-base disorders, renal replacement therapy,
MEDICARE PART A BULLETIN BILLING REQUIREMENTS FOR CLAIMS WITH DATES OF SERVICE ON OR AFTER APRIL1, 1998, FOR ORAL ANTI-NAUSEA DRUGS AS FULL THERAPEUTIC REPLACEMENTS FOR INTRAVENOUS DOSAGE FORMS AS PART OF A CANCER CHEMOTHERAPEUTIC REGIMEN ATTENTION MEDICARE BUSINESS OFFICE MANAGER : Please distribute to all appropri- ate health care personnel. The purpose of this bulletin is to formerly pu